Companies / Debios Diagnostics

Medical device company profile

Debios Diagnostics

Spanish IVD developer advancing urine-based tests for non-invasive detection and monitoring of renal fibrosis.

Medical Device Manufacturer and DeveloperDiagnostics & ImagingIn Vitro Diagnostics

Headquarters🇪🇸Badalona, Catalonia, Spain

Founded2023

Commercial statusIn developmentFIBROKIT renal-fibrosis assays in development and clinical validation.

Employees2–10 ^[5]LinkedIn company-size range · Checked 2026-11-04

Estimated revenueNot confirmed

Official websitedebiosdx.com ↗

Company overview

Debios Diagnostics is a Spanish in vitro diagnostics company founded in 2023 and based in Badalona, Catalonia. A spin-off of the Germans Trias i Pujol Research Institute, or IGTP, it is led by CEO Joan Grasas and develops non-invasive diagnostic tools for kidney and genitourinary disease.

Its lead FIBROKIT programme uses urinary vitronectin as a biomarker of renal fibrosis. Development covers two complementary formats: FIBROKIT-ELISA for quantitative laboratory testing and FIBROKIT-LF, a rapid-test format intended to support more frequent monitoring, potentially outside the hospital.

Debios and IGTP are jointly advancing the PROMORFI project through 2028, including biomarker validation and a prospective clinical study. The programme is intended to evaluate clinical usefulness and future care pathways; home monitoring and broader chronic-kidney-disease applications remain development objectives.

^{[1][2][3][4][5]}

Leadership

4 people

Joan Grasas, MBAChief Executive Officer ^[3]

Marta Clos, PhDCo-founder & Chief Technology Officer ^[3]

Francesc E. Borràs, PhDCo-founder & Chief Scientific Officer ^[3]

Jordi Bover, MDCo-founder & Clinical Advisory Board Director ^[3]

Products & regulatory status How does MedTechIndex get this information?

Summary

The PROMORFI programme is designed to develop and clinically validate FIBROKIT in chronic kidney disease, including biomarker validation in patient cohorts and a prospective clinical trial. IGTP identifies laboratory ELISA and rapid-test formats as complementary development pathways. ^[4]

The rapid-test format’s proposed use for home or remote monitoring is a future application. The clinical programme should not be read as authorization for patient self-testing or as proof that FIBROKIT can replace biopsy across all kidney-disease settings. ^[4]

Regulatory snapshot How to read this snapshot

U.S. FDA

—
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-04.

Scope: selected product families.

Commercial portfolio snapshot

No commercially marketed product portfolio has been established in the reviewed material.

Commercial development

Debios researcher Marta Clos working in the laboratory with a FIBROKIT test-kit box visible — Image: IGTP / Debios Diagnostics

Urine-based in vitro diagnostic platform

FIBROKIT renal-fibrosis assays ↗

Development programme using urinary vitronectin to assess renal fibrosis. FIBROKIT-ELISA is intended for quantitative laboratory testing; FIBROKIT-LF is a rapid-test format under development for periodic monitoring. ^[4]

In development · Clinical validation programme

Activity & Milestones

2 events

2026-03-12 · Clinical

PROMORFI validation programme announced

IGTP described a joint Debios–IGTP project running through 2028, with a total project budget exceeding€1.7 million; the amount is not Debios company funding alone. ^[4]

2023 · Company